KLOW blend calculator
KLOW is four compounds in one vial: GHK-Cu, BPC-157, TB-500 and KPV. Four targets, four ceilings, four frequencies, and exactly one draw volume to satisfy them all. This page works out what that draw actually delivers to each.
Set your vial composition, water volume, experience level and body weight. The per-component breakdown, the three-phase titration table, the per-component frequency table and the supplies plan all recompute. Every dose figure is read from the Klarovel engine’s dose table, never typed into the page.
Vial composition
Vial contents, not doses. Confirm against the label on the vial in front of you before you mix.
Bacteriostatic water added
Experience with injectable peptides
Body weight
Standard phase, single shared draw
12.0 units
0.12 ml on a 100-unit insulin syringe
GHK-Cu
on target1.5 mg
target 1.5 mg, ceiling 2 mg
BPC-157
on target300 mcg
target 300 mcg, ceiling 500 mcg
TB-500 (Thymosin Beta-4)
under target0.3 mg
target 2.4 mg, ceiling 2.5 mg
KPV (Lys-Pro-Val)
on target300 mcg
target 300 mcg, ceiling 500 mcg
The draw is set by GHK-Cu, which reaches its target first. Every other component is read off the same draw because a blend has one ratio.
Per-component breakdown at every draw volume
What each draw volume actually delivers per component at 4 ml of bacteriostatic water and the vial composition selected above. These are mathematical breakdowns of the vial, not dose recommendations. The targets and ceilings are in the titration table below.
| Draw | Volume | GHK-Cu | BPC-157 | TB-500 (Thymosin Beta-4) | KPV (Lys-Pro-Val) |
|---|---|---|---|---|---|
| 2 units | 0.02 ml | 0.25 mg | 50 mcg | 0.05 mg | 50 mcg |
| 4 units | 0.04 ml | 0.5 mg | 100 mcg | 0.1 mg | 100 mcg |
| 5 units | 0.05 ml | 0.625 mg | 125 mcg | 0.125 mg | 125 mcg |
| 6 units | 0.06 ml | 0.75 mg | 150 mcg | 0.15 mg | 150 mcg |
| 8 units | 0.08 ml | 1 mg | 200 mcg | 0.2 mg | 200 mcg |
| 10 units | 0.1 ml | 1.25 mg | 250 mcg | 0.25 mg | 250 mcg |
| 12 units | 0.12 ml | 1.5 mg | 300 mcg | 0.3 mg | 300 mcg |
| 15 units | 0.15 ml | 1.875 mg | 375 mcg | 0.375 mg | 375 mcg |
| 20 units | 0.2 ml | 2.5 mg | 500 mcg | 0.5 mg | 500 mcg |
| 25 units | 0.25 ml | 3.125 mg | 625 mcg | 0.625 mg | 625 mcg |
| 30 units | 0.3 ml | 3.75 mg | 750 mcg | 0.75 mg | 750 mcg |
| 40 units | 0.4 ml | 5 mg | 1000 mcg | 1 mg | 1000 mcg |
| 50 units | 0.5 ml | 6.25 mg | 1250 mcg | 1.25 mg | 1250 mcg |
Arithmetic over the vial composition and your water volume. The display unit per component is the unit that component's row declares in the engine dose table.
Phase by phase titration
Three phases, in the order the engine escalates a dose: opening, standard, then upper. Every figure below is the beginner row of the engine dose table for that component, after the modifiers your inputs trigger. Change experience level, weight or age above and the whole table recomputes.
Phase 1, opening dose
draw 8.0 units
| Component | Delivered | Target | Draw for target | Ceiling |
|---|---|---|---|---|
| GHK-Cu | 1 mg | 1 mg | 8.0 units | 2 mg |
| BPC-157 | 200 mcg | 250 mcg | 10.0 units | 500 mcg |
| TB-500 (Thymosin Beta-4) | 0.2 mg | 2.4 mg | 96.0 units | 2.5 mg |
| KPV (Lys-Pro-Val) | 200 mcg | 250 mcg | 10.0 units | 500 mcg |
The components' own targets are reached 12x apart in draw volume, so one draw cannot satisfy them all. BPC-157, TB-500 (Thymosin Beta-4), KPV (Lys-Pro-Val) land under target at this draw. Reaching that target would mean drawing further and pushing another component past its ceiling, which is why the volume stops here.
- TB-500 (Thymosin Beta-4) is weight sensitive in the catalog at 0.03 mg/kg, so 80 kg sets the target rather than the fixed phase figure.
Phase 2, standard dose
draw 12.0 units
| Component | Delivered | Target | Draw for target | Ceiling |
|---|---|---|---|---|
| GHK-Cu | 1.5 mg | 1.5 mg | 12.0 units | 2 mg |
| BPC-157 | 300 mcg | 300 mcg | 12.0 units | 500 mcg |
| TB-500 (Thymosin Beta-4) | 0.3 mg | 2.4 mg | 96.0 units | 2.5 mg |
| KPV (Lys-Pro-Val) | 300 mcg | 300 mcg | 12.0 units | 500 mcg |
The components' own targets are reached 8x apart in draw volume, so one draw cannot satisfy them all. TB-500 (Thymosin Beta-4) lands under target at this draw. Reaching that target would mean drawing further and pushing another component past its ceiling, which is why the volume stops here.
- TB-500 (Thymosin Beta-4) is weight sensitive in the catalog at 0.03 mg/kg, so 80 kg sets the target rather than the fixed phase figure.
Phase 3, upper dose
draw 16.0 units
| Component | Delivered | Target | Draw for target | Ceiling |
|---|---|---|---|---|
| GHK-Cu | 2 mg | 2 mg | 16.0 units | 2 mg |
| BPC-157 | 400 mcg | 400 mcg | 16.0 units | 500 mcg |
| TB-500 (Thymosin Beta-4) | 0.4 mg | 2.4 mg | 96.0 units | 2.5 mg |
| KPV (Lys-Pro-Val) | 400 mcg | 400 mcg | 16.0 units | 500 mcg |
The components' own targets are reached 6x apart in draw volume, so one draw cannot satisfy them all. TB-500 (Thymosin Beta-4) lands under target at this draw. Reaching that target would mean drawing further and pushing another component past its ceiling, which is why the volume stops here.
- TB-500 (Thymosin Beta-4) is weight sensitive in the catalog at 0.03 mg/kg, so 80 kg sets the target rather than the fixed phase figure.
Targets, upper bounds and ceilings read from dose_protocols, the engine's dose table. Weight scaling applies only where PEPTIDE_CATALOG flags a component weight sensitive. The 0.75x age reduction is the engine's own contraindication rule for age 65 and over.
What your body weight does, and does not, change
Weight sensitive: TB-500 (Thymosin Beta-4) at 0.03 mg/kg. The engine catalog carries a per-kilogram factor for this component, so the weight you entered sets the target directly and is then held inside the beginner ceiling.
Not weight sensitive: GHK-Cu, BPC-157, KPV (Lys-Pro-Val). The catalog does not flag these components weight sensitive and the dose calculator applies no weight scaling of its own, so changing the weight field does not move their target. Scaling every compound by body mass would be an invention, so the tool does not do it.
Supplies for one cycle
One on-cycle runs 8 weeks because that is the shortest on-period among the components, set by GHK-Cu. A single vial cannot be cycled per component, so the shortest on-period governs, followed by 8 weeks off.
Options come from the components' own frequency strings: GHK-Cu is once daily, BPC-157 is once to twice daily, TB-500 (Thymosin Beta-4) is twice weekly, KPV (Lys-Pro-Val) is once daily. Where those disagree there is no single correct value, so the default is the most conservative one the data supports.
| Cycle length | 8 weeks |
|---|---|
| Administrations per week | 2 |
| Total administrations | 16 |
| Vials | 1 |
| Insulin syringes | 16 (30-unit holds the draw) |
| Bacteriostatic water | 4 ml, 1 bottle of 10 ml |
Cycle length from PEPTIDE_CATALOG cycling data. Administrations per week derived from the frequency string on each component's dose row. Vial and syringe counts are arithmetic over your draw volume and water volume.
Component reference
Route, timing, frequency and cycling per component, read from the engine catalog.
| Component | Route | Timing | Frequency | Cycle | Loading phase |
|---|---|---|---|---|---|
| GHK-Cu | subcutaneous | Any time | once daily | 8 on / 8 off | None |
| BPC-157 | subcutaneous | Any time | once to twice daily | 12 on / 4 off | None |
| TB-500 (Thymosin Beta-4) | subcutaneous | Any time | twice weekly | 12 on / 4 off | 4 weeks at 2x |
| KPV (Lys-Pro-Val) | subcutaneous | Any time | once daily | 8 on / 4 off | None |
Route, timing and cycling from PEPTIDE_CATALOG. Frequency from the beginner row of dose_protocols.
What a fixed blend cannot do, stated plainly
A blend is one ratio in one vial. There is exactly one draw volume, and it has to serve every component at once. When the ratio does not match the ratio of the components' own targets, something has to give: either a component lands under its target, or another is pushed toward its ceiling. The table above says which, for your inputs, rather than printing a single volume and leaving it unresolved.
Contraindications are the second limit. A protocol can drop one compound and keep the rest. A blend cannot, because the compounds share a vial. If a health condition rules out one component, it rules out the vial.
A Klarovel protocol is built from your health data. Blood work is optional and sharpens the result, but it never gates it. The engine resolves contraindications, sets the dose envelope by experience level, removes incompatible pairs and sets the cycling schedule. That is the difference between a calculator and a protocol.
Save your reconstitution. Get the protocol it belongs in.
Free founding-member access while spots last. We'll send your reconstitution + a link to claim your slot.
Questions
- What is in the KLOW blend?
- Four compounds co-lyophilised in one vial: GHK-Cu, a copper-binding tripeptide; BPC-157, a pentadecapeptide originally identified in gastric juice; TB-500, a synthetic fragment of thymosin beta 4; and KPV, a tripeptide from the C-terminal end of alpha-MSH. Compositions vary between presentations, so enter the milligram amounts from your own label.
- What is the KLOW frequency, per component?
- Each component carries its own frequency in the engine dose table, and they are not identical. The component reference table on this page lists them verbatim for the experience level you selected. Where they do not overlap, the page says so instead of picking one, because a single vial forces one schedule and that is a genuine limitation of a fixed blend.
- How does one draw serve four compounds?
- It takes the largest volume at which none of the four passes its own upper bound in the engine dose table, then reports what that draw delivers to each and whether it is on, under or over that component’s target. With four components the odds that all four land on target at one volume are low, and the table shows which ones do not.
- What does KLOW add over GLOW?
- KPV. GLOW is the same blend without it. Adding a fourth compound adds a fourth target and a fourth ceiling that the shared draw has to respect, and a fourth frequency that the shared schedule has to accommodate. There is a separate GLOW calculator on this site if you are running the three-component vial.
- Does body weight change the doses?
- Only for TB-500. The engine catalog flags it weight sensitive and carries a per-kilogram factor, so the weight you enter sets its target. GHK-Cu, BPC-157 and KPV carry no such factor and the dose calculator applies no generic weight scaling, so their targets do not move with weight. The page states which components respond and which do not.
- Four compounds at once: is that a normal protocol?
- It is more compounds than the Klarovel engine would open with for most people. The engine caps a protocol by experience level, at two compounds at the lowest levels and four at the highest, and a blend cannot be trimmed because the compounds share a vial. The calculator flags when your selected experience level implies a lower cap than the blend contains.
- Do the four components want the same cycle length?
- No, and a shared vial cannot resolve that either. The supplies table takes the shortest on-period among the four and names the component that set it. The component reference table shows each compound’s own on and off weeks so you can see where they diverge.
- What if a health condition rules out one of the four?
- Then it rules out the vial. That is the structural difference between a blend and a protocol: a protocol drops one compound and keeps the rest, and the Klarovel engine surfaces the reason rather than silently omitting it. A blend has no such option, because the compounds are already mixed.
- Is this calculator free?
- Yes. No account, no paywall, no usage limit. The protocol engine behind it is a separate product, but the calculator is open.
- Does Klarovel sell this blend?
- No. Klarovel is the protocol layer: a questionnaire, a deterministic rules engine and a generated protocol. Any product is fulfilled by partner suppliers, not by Klarovel. This page exists because the arithmetic of a fixed-ratio vial is genuinely hard to do in your head, not to move a product.
- Is this medical advice?
- No. It is arithmetic over published dose data, presented as a reference. It is not a prescription and not a recommendation to use any compound. Discuss peptide use with a qualified clinician.
Other blend calculators
Same engine, different vial. Pick the page that matches what you actually have in front of you: the component list and the ratio change the arithmetic completely.
References
These papers cover the mechanism and clinical context of GHK-Cu, BPC-157, thymosin beta 4 (the parent protein TB-500 is a fragment of) and the alpha-MSH tripeptide KPV.
The dose figures on this page are not sourced from these papers. They are read from the Klarovel engine's own dose table, which is cited inline wherever a number appears. These references cover mechanism, pharmacology and clinical context.
42 references, every identifier resolved against NCBI on 2026-07-30. Per peptide, a relevance-sorted esearch was run and every returned id was resolved through esummary. Any id esummary could not resolve was dropped, and any record carrying the 'Retracted Publication' pubtype was dropped. Titles, journals, years and first authors below are the values esummary returned, not authored text. One retracted record was dropped: PMID 37696839 (thymosin beta 4 query).
- 1.Pickart L et al. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci 2018. PMID 29986520 PMC6073405
- 2.Pickart L et al. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int 2015. PMID 26236730 PMC4508379
- 3.Pickart L et al. The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: implications for cognitive health. Oxid Med Cell Longev 2012. PMID 22666519 PMC3359723
- 4.Dou Y et al. The potential of GHK as an anti-aging peptide. Aging Pathobiol Ther 2020. PMID 35083444 PMC8789089
- 5.Fu SC et al. Tripeptide-copper complex GHK-Cu (II) transiently improved healing outcome in a rat model of ACL reconstruction. J Orthop Res 2015. PMID 25731775
- 6.Kang YA et al. Copper-GHK increases integrin expression and p63 positivity by keratinocytes. Arch Dermatol Res 2009. PMID 19319546
- 7.Pickart L et al. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed 2008. PMID 18644225
- 8.Wang X et al. GHK-Cu-liposomes accelerate scald wound healing in mice by promoting cell proliferation and angiogenesis. Wound Repair Regen 2017. PMID 28370978
- 9.Chang CH et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985) 2011. PMID 21030672
- 10.Seiwerth S et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Front Pharmacol 2021. PMID 34267654 PMC8275860
- 11.Gwyer D et al. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res 2019. PMID 30915550
- 12.Józwiak M et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel) 2025. PMID 40005999 PMC11859134
- 13.Vasireddi N et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J 2025. PMID 40756949 PMC12313605
- 14.Lee E et al. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med 2025. PMID 40131143
- 15.McGuire FP et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med 2025. PMID 40789979 PMC12446177
- 16.Sikiric P et al. The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity. Pharmaceuticals (Basel) 2024. PMID 38675421 PMC11053547
- 17.Goldstein AL et al. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther 2012. PMID 22074294
- 18.Kleinman HK et al. Thymosin β4 Promotes Dermal Healing. Vitam Horm 2016. PMID 27450738
- 19.Pipes GT et al. Cardioprotection by Thymosin Beta 4. Vitam Horm 2016. PMID 27450736
- 20.Smart N et al. Thymosin beta-4 is essential for coronary vessel development and promotes neovascularization via adult epicardium. Ann N Y Acad Sci 2007. PMID 17495252
- 21.Zhang Y et al. Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion. Cardiovasc Res 2025. PMID 41229390
- 22.Tan WKY et al. Sources of variability in quantifying circulating thymosin beta-4: literature review and recommendations. Expert Opin Biol Ther 2018. PMID 29502471
- 23.Nachmias VT et al. Small actin-binding proteins: the beta-thymosin family. Curr Opin Cell Biol 1993. PMID 8448031
- 24.Mendias CL et al. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med 2026. PMID 41966639
- 25.Dalmasso G et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology 2008. PMID 18061177 PMC2431115
- 26.Kannengiesser K et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis 2008. PMID 18092346
- 27.Getting SJ et al. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. J Pharmacol Exp Ther 2003. PMID 12750433
- 28.Elliott RJ et al. alpha-Melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells. J Invest Dermatol 2004. PMID 15102092
- 29.Luger TA et al. New insights into the functions of alpha-MSH and related peptides in the immune system. Ann N Y Acad Sci 2003. PMID 12851308
- 30.Ichiyama T et al. The neuroimmunomodulatory peptide alpha-MSH. Ann N Y Acad Sci 2000. PMID 11268347
- 31.Catania A et al. The neuropeptide alpha-MSH in host defense. Ann N Y Acad Sci 2000. PMID 11268348
- 32.Cutuli M et al. Antimicrobial effects of alpha-MSH peptides. J Leukoc Biol 2000. PMID 10670585
- 33.Xiao B et al. Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Mol Ther 2017. PMID 28143741 PMC5498804
- 34.Viennois E et al. Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model. Cell Mol Gastroenterol Hepatol 2016. PMID 27458604 PMC4957955
- 35.Pawar KR et al. Stability-indicating HPLC assay for lysine-proline-valine (KPV) in aqueous solutions and skin homogenates. Biomed Chromatogr 2015. PMID 25298219
- 36.Pawar K et al. Transdermal Iontophoretic Delivery of Lysine-Proline-Valine (KPV) Peptide Across Microporated Human Skin. J Pharm Sci 2017. PMID 28343991
- 37.Shao W et al. In situ mucoadhesive hydrogel capturing tripeptide KPV: the anti-inflammatory, antibacterial and repairing effect on chemotherapy-induced oral mucositis. Biomater Sci 2021. PMID 34846053
- 38.Land SC et al. Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists. Int J Physiol Pathophysiol Pharmacol 2012. PMID 22837805 PMC3403564
- 39.Bonfiglio V et al. Effects of the COOH-terminal tripeptide alpha-MSH(11-13) on corneal epithelial wound healing: role of nitric oxide. Exp Eye Res 2006. PMID 16965771
- 40.Brzoska T et al. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev 2008. PMID 18612139
- 41.Gravina AG et al. The Melanocortin System in Inflammatory Bowel Diseases: Insights into Its Mechanisms and Therapeutic Potentials. Cells 2023. PMID 37508552 PMC10378568
- 42.Sung J et al. Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-κB pathway. Tissue Cell 2025. PMID 40073467
Beyond the arithmetic
A protocol resolves what a blend cannot.
The Klarovel engine reads your health data, resolves contraindications, sets the dose envelope by experience level, removes incompatible pairs and builds the cycling and monitoring schedule. Blood work is optional and sharpens the result. It is never required.